The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTrials & Tribulations

MRI-guided radiotherapy for prostate cancer: Lessons from the MIRAGE trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute defines precision medicine in cancer as a strategy that “uses specific information about a person’s tumor to help make a diagnosis, plan treatment, find out how well treatment is working, or make a prognosis.”1 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Amar U. Kishan, MD
Associate professor, Chief of Genitourinary Oncology Service, Vice chair of clinical and translational research, Department of Radiation Oncology, University of California, Los Angeles
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

GammaTile delivers superior tumor control vs. standard-of-care for newly diagnosed operable brain metastases

GammaTile showed superiority in the primary endpoint of the study. Patients who received GammaTile lived longer without tumor regrowth, reducing the risk of either tumor recurrence or death by 50% reduction compared to standard of care, according to interim results from the ROADS clinical trial, which evaluated GammaTile versus standard of care in patients with operable, newly diagnosed brain metastases.
Byline
Amar U. Kishan, MD
Associate professor, Chief of Genitourinary Oncology Service, Vice chair of clinical and translational research, Department of Radiation Oncology, University of California, Los Angeles
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account